Abstract
Tuberculosis (TB) is an old infectious disease caused by Mycobacterium tuberculosis infection. Vaccination is the most effective way to prevent and control TB. However, there is relatively little literature that systematically analyzes the progress of new TB vaccine research from a bibliometric perspective. This study was conducted to examine the development of TB vaccines over the past 20 years and to identify research priorities and directions for the future. The Science Citation Index Expanded (SCI-E) of the Web of Science Core Collection (WOSCC) database was selected to search the literature related to TB vaccines. The countries, institutions, authors, journals, references, and keywords of each publication were analyzed and visualized using the VOSviewer, CiteSpace, and Bibliometrix software. Furthermore, GraphPad Prism and Microsoft Excel 365 were also used for statistical analysis. As of 20 October 2022, 7960 publications related to TB vaccines were identified with 288,478 citations. The United States of America (USA) accounted for the largest share (2658, 33.40%), followed by the United Kingdom (UK, 1301, 16.34%), and China (685, 8.6%). Regarding affiliations, the University of London had the most publications (427) and shared the highest H-index (76) with the Statens Serum Institut of Denmark. In terms of the number of articles for the journals and authors, the journal Vaccine ranked first with 629 articles. Professor Peter Anderssen has published the highest number of papers (160). The burst keywords and thematic maps analysis showed that future trends in TB vaccine development would focus on exploring the interaction mechanisms between M. tuberculosis and the host. The number of publications on TB vaccines has grown over the past two decades. Developed countries play a significant role in TB vaccine research, and developing countries are fast catching up. We believe that future research will be aimed at understanding the fine molecular mechanisms of host-pathogen interaction, leading to the development of better TB vaccines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
